# Prioritizing disease-causing metabolic genes by integrating metabolomics with whole exome sequencing data

3

Michiel Bongaerts<sup>1\*</sup>, Ramon Bonte<sup>1</sup>, Serwet Demirdas<sup>1</sup>, Hidde Huidekoper<sup>2</sup>, Janneke
Langendonk<sup>3</sup>, Martina Wilke<sup>1</sup>, Walter de Valk<sup>1</sup>, Henk J. Blom<sup>1</sup>, Marcel J.T. Reinders<sup>4</sup> and George
J. G. Ruijter<sup>1\*</sup>

7

<sup>1</sup> Department of Clinical Genetics, Erasmus Medical Centre, Dr. Molewaterplein 40, 3015 GD Rotterdam,
The Netherlands

<sup>2</sup> Department of Pediatrics, Center for Lysosomal and Metabolic Diseases, Erasmus Medical Centre, Dr.

11 Molewaterplein 40, 3015 GD Rotterdam, The Netherlands

<sup>3</sup> Department of Internal Medicine, Center for Lysosomal and Metabolic Diseases, Erasmus Medical

13 Centre, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands

<sup>4</sup> Faculty of Electrical Engineering, Mathematics and Computer Science, TU Delft, Van Mourik
 Broekmanweg 6, 2628 XE, Delft, The Netherlands;

- 16 <sup>\*</sup> Corresponding authors
- 17

Abstract: The integration of metabolomics data with sequencing data is a key step towards improving the 18 19 diagnostic process for finding the disease-causing gene(s) in patients suspected of having an inborn error 20 of metabolism (IEM). The measured metabolite levels could provide additional phenotypical evidence to 21 elucidate the degree of pathogenicity for variants found in metabolic genes. We present a computational 22 approach, called *Reafect*, that calculates for each reaction in a metabolic pathway a score indicating whether 23 that reaction is being deficient or not. When calculating this score, Reafect takes multiple factors into 24 account: the magnitude and sign of alterations in the metabolite levels, the reaction distances between 25 metabolites and reactions in the pathway, and the biochemical directionality of the reactions. We applied Reafect to untargeted metabolomics data of 72 patient samples with a known IEM and found that in 80% 26 27 of the cases the correct deficient enzyme was ranked within the top 5% of all considered enzyme 28 deficiencies. Next, we integrated *Reafect* with CADD scores (a measure for variant deleteriousness) and 29 ranked the potential disease-causing genes of 27 IEM patients. We observed that this integrated approach 30 significantly improved the prioritization of the disease-causing genes when compared with the two 31 approaches individually. For 15/27 IEM patients the correct disease-causing gene was ranked within the 32 top 0.2% of the set of potential disease-causing genes. Together, our findings suggest that metabolomics data improves the identification of disease-causing genetic variants in patients suffering from IEM. 33

# 34 Introduction

35 DNA sequencing methods such as whole exome sequencing (WES) and whole genome sequencing (WGS) 36 are powerful techniques to identify the pathogenic genetic variant(s) in patients suspected of a genetic 37 disease (Pronicka, et al., 2016) (Wright, et al., 2018) (Stavropoulos, et al., 2016). Nevertheless, a single 38 WES typically generates tens of thousands of variants (Wright, et al., 2018). With the reduced costs for 39 sequencing, WGS becomes increasingly popular, generating even a few million of variants per patient 40 (Wright, et al., 2018). Numerous filtering strategies have been developed to reduce the number of variants 41 which need to be manually inspected. The Combined Annotation Dependent Depletion (CADD) score is 42 widely explored as one of these filtering strategies (Rentzsch, et al., 2018); prioritizing variants such as 43 single nucleotide variants (SNV), deletions and insertions (InDels) in patients. CADD scores employ a 44 machine learning based approach where 63 conservational - and functional genomic metrics are combined 45 into a single metric. After various filtering steps, the investigator still needs to evaluate a substantial number of variants manually. The pathogenicity of these rare or novel variants is often unknown, leading to a 46 47 clinically dissatisfactory classification.

48

49 Functional studies may provide evidence whether a variant of unknown significance should be considered pathogenic or not. For this purpose, metabolomics is catching more and more interest since it has the 50 51 potential to resolve the degree of pathogenicity for genetic variants which are expected to have an effect on 52 the patient's metabolism, i.e. inborn errors of metabolism (IEM) (Kerkhofs, et al., 2020) (Alaimo, et al., 53 2020) (Linck, et al., 2020). Some strategies have already been developed for this purpose; Haijes et al. 54 applied expert knowledge to develop an algorithm that matches metabolic signatures obtained from 55 metabolomics with expected metabolic signatures caused by each IEM, thereby ranking potential enzymatic deficiencies (Haijes, et al., 2020). Similarly, Baumgartner et al. explored the use of classification algorithms 56 57 to distinguish multiple IEM based on differences in metabolite levels (Baumgartner, et al., 2004). However, training such a classifier requires data from multiple patients having the same IEM and since more than a 58 59 1000 different IEM exist with an overall birth prevalence of 51 per 100.000 (Waters, et al., 2018) the 60 creation of large cohorts is challenging, thereby hampering the use of classification algorithms. To 61 overcome this limitation, Messa et al. explored the use of metabolic networks to simulate IEM specific metabolic profiles, which they then compared with real IEM profiles using a Siamese neural network to 62 rank the most probable matching (simulated) IEM (Messa, et al., 2020). Another strategy involves the use 63 of gene-metabolite sets for which an enrichment score can be calculated to rank potential affected genes 64 65 (Kerkhofs, et al., 2020). Similarly, MetPropagate (Linck, et al., 2020) uses gene-metabolite set enrichment 66 scores, but additionally propagates these scores through a protein-protein network to rank potentially 67 affected genes. The main concern with these approaches is that enrichment scores require (Z-score) cutoffs

68 for metabolite levels, potentially excluding subtle aberrations that do not exceed the thresholds. In a 69 different approach, Pirhaji et al. developed a tool, called *PIUMet*, that integrates metabolomics data with 70 other omics data (Pirhaji, et al., 2016). PIUMet automatically annotates mass spectrometry (MS) features while inferring disease-associated pathways using a prize-collecting Steiner Forest algorithm. Still, we 71 72 believe that most approaches did not fully exploited some crucial interconnected characteristics of IEM, 73 i.e.: 1) the direction (increased or decreased) and 2) the magnitude of alterations in the metabolite levels, 74 3) pathway information including the biochemical directionality of reactions, and 4) reaction distances 75 between metabolites and reactions.

76

77 To integrate metabolomics in WES, and potentially WGS, analysis, we developed an algorithm, called 78 *Reafect* (**Rea**ction defect). *Reafect* combines information of metabolic pathways from KEGG (Kanehisa, 79 2000) and the metabolite Z-scores obtained from annotated metabolomics data to calculate a 'deficient 80 reaction score' for each reaction. Higher scores imply that there is more evidence of that reaction being 81 deficient and vice versa. Our algorithm differs fundamentally from the approaches mentioned earlier, since 82 it is solely based on pathway information, and uses the metabolite Z-scores in a continuous fashion without using cutoff values. Reafect furthermore takes the directionality of the reactions and the sign of the Z-scores 83 84 into account when calculating the *deficient reaction scores*. We evaluated *Reafect's performance on 36* 85 distinct IEM using 72 plasma samples from patients diagnosed with an IEM. 86

Since each reaction is associated with genes coding for the enzyme catalyzing that reaction, we used *Reafect's deficient reaction scores* in combination with *CADD* scores as an integrated model for prioritizing potentially disease-causing metabolic genes. To evaluate this approach, we studied 27 IEM patients for which the pathogenic variant was identified and untargeted metabolomics data was obtained. This integrated model showed a significant improvement on ranking the correct disease-causing genes when compared with using solely *Reafect* or *CADD* scores.

- 93
- 94

# 95 **Results**

#### 96 Reafect

97 An enzymatic deficiency generally leads to a build-up of the reaction substrate(s) and shortages of the product(s) formed by that reaction. Z-scores obtained from annotated metabolomics (see Methods) can be 98 99 used to detect the accumulation of these substrates (i.e. positive Z-scores) as well as shortages of the products (i.e. negative Z-scores). Although the accumulation and shortage of metabolites occur for the 100 101 metabolites directly involved in the deficient reaction, aberrant metabolite levels will also propagate 102 through a biochemical pathway, leading to changes in metabolite levels that are multiple reaction steps away from the deficient reaction. We used this dogma to develop an algorithm, called Reafect, that 103 104 calculates for each reaction in a pathway a score that reflects how deficient that reaction is. We called this score the deficient reaction score or S<sub>R</sub> score (see Methods for details). To calculate this score, Reafect 105 106 weighs metabolite levels (Z-scores) which are further away from the considered reaction to a lesser extent 107 than metabolite levels closer to the putative reaction, since we assume that more distant metabolites give less information about the reaction deficiency. For this purpose, *Reafect* uses a weighted version of the 108 109 observed Z-scores, called 'effective Z-scores', and which are always relative to the considered reaction for 110 which the *deficient reaction score* is calculated (see Figure 1). The *effective Z-score* is determined by 111 calculating a total decay factor over a reaction path when going from the metabolite (with Z-score) to that 112 reaction. The more steps away from the considered reaction, the more the observed Z-score is decayed, thereby resulting in a lower (absolute) effective Z-score. To constrain the number of model parameters, we 113 114 used three different decay factors (a,b,c) and distinguished five different decay types: 1) a decay factor a 115 for a metabolite with a positive Z-score taking a step downstream towards the considered reaction, 2) a 116 decay factor b for a metabolite with a positive Z-score taking a step upstream towards the considered 117 reaction, 3) a decay factor a for a metabolite with a negative Z-score taking a step upstream, 4) a decay 118 factor b for a metabolite with a negative Z-score taking a step downstream and 5) a decay factor c for 119 reversible reactions (independent of the Z-score sign) taking one step in the direction of the considered 120 reaction. We want to emphasize that *Reafect* describes reaction paths as a chain of metabolite and reaction 121 nodes (in a graph) to track all pathway information (see Figure 1). Consequently, a reaction step is either a 122 step from metabolite to reaction, or from reaction to metabolite. For example, consider a metabolite with a positive Z-score which takes three downstream steps to get to the considered reaction (Figure 1a,  $m_2$  to  $R_3$ ). 123 The *effective Z-score* for this metabolite would then be given by the Z-score multiplied by  $a^3$ , thus having 124 a total decay factor of  $a^3$ . Similarly, if this metabolite had a negative Z-score the total decay factor for this 125 reaction path would have been  $b^3$ . Obviously, a reaction path could also be more complex, resulting for 126 example in a total decay factor of  $c^2 b a^2$ . We justify the introduction of a and b, by realizing that when a > b127

the *effective Z-scores* remain relatively high for positive Z-scores located upstream of a deficiency, and the same holds for negative Z-scores downstream of the deficiency. The values of these decay factors (*a*, *b* and *c*) are selected using the metabolomics data from 72 IEM patient samples (see Section Tuning the model *parameters*). Subsequently, *Reafect* aggregates all *effective Z-scores* resulting in the *deficient reaction score* (or S<sub>R</sub> score) where it takes into account whether a certain *effective Z-score* was located downstream or upstream of the considered reaction (see Methods, Equation 6).

Finally, *Reafect* prioritizes all reactions by sorting the  $S_R$  scores on their magnitude, with higher scores indicating that a reaction is more likely to be deficient. Next to prioritizing the reactions, *Reafect* can prioritize enzymes and corresponding genes on their potential of being deficient. As enzymes can be involved in multiple reactions the final  $S_R$  score for an enzyme is taken to be the maximum  $S_R$  score of the set of reactions the enzyme may catalyze (Method).

139




Figure 1. Illustration of *Reafect*. A circle indicates a metabolite and a square a reaction (node), with the horizontal arrows indicating
the directionality of the reaction. The vertical grey bars (with dot) indicate the observed Z-scores; pointing upwards indicating a
positive Z-score and vice versa. The black dotted bars indicate the *effective Z-score* from the perspective of reaction R<sub>3</sub>. Note that

144 Reafect determines for each reaction a deficient reaction score but in these figures only the results are shown for  $R_3$ . A) Reaction 145 R<sub>3</sub> is deficient. The *effective Z-scores* decay when going away from R<sub>3</sub> as visualized by the reduced magnitude of the black bars. 146 The *deficient reaction score*, illustrated by the blue bar on R<sub>3</sub>, is high since we observe net positive *effective Z-scores* upstream of 147 R<sub>3</sub> and net negative *effective Z-scores* downstream of R<sub>3</sub>. B) R<sub>3</sub> is not deficient and metabolite Z-scores around the reaction are 148 normal, thereby resulting in a low *deficient reaction score*. Note that the blue bar at  $R_3$  is small. C)  $R_3$  is not deficient, but has still 149 a relatively high *deficient reaction score*. Note that although the observed Z-scores for  $m_3$  and  $m_4$  are equal, the resulting *effective* 150 Z-scores are different since the decay of the Z-scores also depends on the biochemical directionality (and also applies to m<sub>2</sub> and 151 m<sub>5</sub>). Metabolite m<sub>1</sub> has a relatively high observed Z-score, but its effective Z-scores is reduced since it is 5 reaction steps away 152 from R<sub>3</sub>. Reafect calculates per side of the reaction the net effective Z-scores. For example, the effective Z-scores for m<sub>4</sub> and m<sub>5</sub> 153 roughly counter balance each other when looking at the downstream side of R<sub>3</sub>. The upstream side has net positive *effective Z*-154 scores, therefore resulting in a positive deficient reaction score.


155

#### **156 Tuning the model parameters**

157 Per IEM patient, potential deficient enzymes were ranked by their maximum associated  $S_R$  score (Methods) 158 and the rank of the true deficient enzyme in that patient was reported (Figure 4, *Absolute rank*). Since the 159 total number of enzymes on which the ranking was based varied among the patients, we determined the percentile rank (PR) by dividing by the total number of enzymes multiplied by 100% (Methods). A lower 160 161 PR indicates an improved ranking performance and vice versa. The overall performance of Reafect was 162 measured by calculating how often a PR was smaller or equal than a predefined value across the 72 IEM 163 patient samples. When increasing this predefined value a curve is generated as displayed in Figure 3. We 164 used the area under this curve (AUC) to indicate the overall performance of *Reafect*, where higher AUCs 165 imply better performances.

166

167 Since *Reafect* uses three model parameters (a, b, c), we used a parameter sweep over these parameters to explore how the performance (AUC) was affected. We performed a bootstrap procedure to obtain a robust 168 169 performance AUC (Methods). Figure 2 shows these bootstrapped AUCs for each combination of (a, b, c). For region b > a, *Reafect* performs less than for region b < a. This can be understood by realizing that when 170 a > b the *effective Z-scores* for metabolites having positive Z-scores decay faster for downstream steps than 171 for upstream steps (and the opposite for negative Z-scores), resulting in reduced evidence for the deficient 172 173 reaction. Furthermore, for region c < 0.5, *Reafect's* overall performance is poor. The highest performance 174 was reached for a = 0.85, b = 0.35, and c = 0.75 (see Figure 2B). In further evaluations of *Reafect*, we set 175 the parameters a, b, c to these values.





178Figure 2. A) Bootstrapped AUCs (Methods) for different combinations of *Reafect*'s hyper parameters (a,b,c). The colors indicate179the percentage of the maximum obtained AUC. B) Contour plot of the (cubic interpolated) bootstrapped AUCs while fixing c=0.75180and varying a and b. The contour levels indicate the percentage of the maximum AUC reached at a = 0.85, b = 0.35, c = 0.75.

181

#### 182 Enzyme ranking for IEM patients

183 We applied *Reafect* to 72 IEM patient samples and determined the percentile rank (PR) of the true enzyme 184 deficiency. For 61% of these samples the PR was within the top 2.5% of all considered enzyme deficiencies, and for 80% of the samples the PR was within the top 5% (Figure 3). Additionally, we compared *Reafect* 185 with MetPropagate (Linck, et al., 2020), while taking several factors into account such as overlapping 186 187 metabolites and genes between the two approaches to objectively compare the performances (Methods). Based on 65 IEM patient samples, we found that *Reafect* has a 19% increase in the AUC when compared 188 189 to *MetPropagate*. Considering that lower percentile ranks (<10%) are more interesting (Figure 3B), we 190 observe that for this region the partial AUC of *Reafect* is 69% higher than the partial AUC of *MetPropagate*. 191 A detailed overview of the PRs per IEM patient for both approaches can be found in Supplement 1. 192




Figure 3. IEM ranking performances for different approaches as indicated by the legend. Each curve shows the percentage of IEM patient samples for which the percentile rank (PR) of the true enzyme deficiency is within the top x % (horizontal axis) of all considered enzyme deficiencies. Model settings for *Reafect*: a = 0.85, b = 0.35 and c = 0.75. A) Full performance curves. B) Performance curves with PR <= 10%. To perform a meaningful comparison between *Reafect* and *MetPropagate* a subset of the data was analyzed that contained only metabolites and genes that were included in both approaches (Methods). Note that this selection reduced the performance of *Reafect* to 91% of its original performance.

200

201 Figure 4. shows a detailed overview of the results per IEM patient. From this figure it is clear that for the 202 same IEM but different patients, *Reafect* can return different PRs. For example, one patient with maple syrup urine disease (BCKDH) has a PR of 0.36%, whereas for the other patient this is 4.19%. This can be 203 204 explained by the difference in the magnitude of the Z-scores for the disease-related metabolites leucine and isoleucine, namely for the patient with the low rank Z = 6.7 and Z = 5.4, respectively, and for the patient 205 with the higher rank these Z-scores were less extreme, Z = 2.49 and Z = 2.65, respectively. Similarly, for 206 207 two patients having long-chain-3-hydroxyacyl-CoA dehydrogenase deficiency (HADHA), one has a PR of 208 0.54% and for the other this is 1.62%. Again, this difference in PRs can be understood by differences in for example 3-hydroxyhexadecanoylcarnitine, which had a Z-score of Z = 13.3 for the patient with the lower 209 210 PR, while the other was more subtle with Z = 6.4. Also, one patient with carbamoyl phosphate synthetase 211 I deficiency (CPS1) ranked at 1.73%, had Z = 1.8 for L-glutamine, while the other patient (ranked at 19.37%) seemed to have a normal L-glutamine level (Z = 0.2), thereby explaining also the difference 212 213 between these ranks.

Percentile rank (%)

									_		Fe	rcentile rank (7	0)										
									0	i s	2 3	4 5 6	7 8	3 9	10								
TYMP	0.0	0	573	5	40	ASL	0.36	2	557	6	15	CPS1	1.73	10	577	15	33	MMUT	7.89	44	558	3	20
MMUT	0.0	0	588	5	56	BCKDH	0.36	2	557	6	22	OGDH	1.83	10	547	6	12	CPT2	9.01	52	577	4	46
ACY1	0.0	0	547	7	35	ACADM	0.36	2	553	3	35	CBS	2.13	12	563	9	35	MLYCD	10.3	58	563	4	24
MANBA	0.0	0	573	1	37	ACADM	0.51	3	585	3	35	PCCA	2.39	14	585	4	20	отс		65	547	5	12
XDH	0.0	0	537	13	66	GCDH	0.53	3	566	5	46	GLDC	2.52	15	595	14	45		13.32	75	563	7	17
CPT2	0.0	0	537	4	46	HPRT1	0.54	3	558	13	66	GLDC	2.86	17	595	14	45	ACSF3		94 101	524 547	5 6	20 42
PAH	0.0	0	547	3	4	HADHA	0.54	3	557	4	35	PAH	2.86	15	524	3	10	HGD CPS1	18.46 19.37	101	573	8	42
ADSL	0.0	0	577	2	13	PAH	0.54	3	557	5	10	ASL	2.93	16	547	5	15	PSAT1	19.89	107	538	11	45
CPT2	0.0	0	563	4	46	PCCA	0.76	4	524	4	24	MTHFR	3.03	17	561	1	9	GAMT	28.99	160	552	12	45
$ASS_b$	0.0	0	580	6	15	CBS	0.87	5	577	6	8	$IVD_a$	3.16	17	538	7	22	MVK	31.89	184	577	1	21
PAH	0.0	0	563	4	10	OAT	88.0	5	566	12	49	ACADM	3.59	21	585	3	35	HGD	36.23	200	552	3	7
ASL	0.0	0	563	5	15	GLDC	1.01	6	595	14	45	CBS	3.76	22	585	5	8		rank	rank	mes	tion	ıway
$ASS_a$	0.0	0	585	5	15	ACAT1	1.11	6	539	11	56	ACADM	3.76	22	585	3	35		Percentile rank	Absolute rank	Total number of enzymes	Measured metabolites near reaction	Total metabolites in pathway
MCCC2	0.0	0	585	12	56	ACAT1	1.24	7	563	11	56	FAH	3.77	21	557	7	42		Perce	Abs	nber o	es nea	lites i
GCDH	0.18	1	563	5	46	ACADVL	1.42	8	563	3	35	PDHA1	3.92	22	561	1	26				nun le	abolit	letabo
PAH	0.18	1	563	4	10	ACADM	1.53	8	524	3	35	GLDC	4.09	22	538	11	45				Tota	d met	otal m
ACADVL	0.18	1	561	2	35	IVD	1.54	9	585	7	22	BCKDH	4.19	24	573	11	56					easure	F
$IVD_b$	0.19	1	537	7	22	HADHA	1.62	9	557	4	35	FAH	4.64	25	539	3	7					M	
ARG1	0.36	2	563	5	12	MMUT	1.64	9	550	3	20	OTC	6.7	37	552	6	17						
HMGCL	0.36	2	561	11	56	ACADM	1.71	10	585	3	35	PSAT1	6.88	37	538	11	45						
	Percentile rank	Absolute rank	Total number of enzymes	Measured metabolites near reaction	Total metabolites in pathway		Percentile rank	Absolute rank	Total number of enzymes	Measured metabolites near reaction	Total metabolites in pathway		Percentile rank	Absolute rank	Total number of enzymes	Measured metabolites near reaction	Total metabolites in pathway						

#### 214

215 Figure 4. Detailed overview of the ranks of the correct IEM per patient. The first column indicates the PR (for the known deficient 216 enzyme) for a given patient. Blue colors indicate PRs lower than 5%, orange/red colors indicate PRs above 5% (see color bar). The 217 second column shows the absolute rank of the deficient enzyme. The third column indicates the total number of the ranks/ unique 218 enzymes on which the ranking was based (this number varies across patients due to differences in metabolite annotations). The 219 fourth column indicates the number of annotated metabolites in the pathway on which the deficient reaction score was based. The 220 fifth column shows the total number of metabolites present in that pathway. For the HADHA gene, which encodes two enzymatic 221 functions, we selected enzyme EC 1.1.1.211. The patient samples ASS<sub>a</sub> and ASS<sub>b</sub> originate from the same patient, but were acquired 222 on different dates. The same holds for the samples IVD<sub>a</sub> and IVD<sub>b</sub>.

- Some IEM were poorly ranked due to the absence of clear aberrations in the metabolomics data. For both
- patients with alkaptonuria (homogentisate 1,2-dioxygenase deficiency, HGD), homogentisic acid was not
- increased in our analysis (Z = 0.4 and Z = 0.5), which clarifies why *Reafect* poorly ranked these patients.
- 227 The patient with mevalonate kinase deficiency (MVK) was also ranked poorly, which was a consequence

of two reasons: 1) only one metabolite involved in calculating the  $S_R$  score i.e. mevalonic acid, was annotated in the metabolomics data and 2) the Z-score of this metabolite was Z = 0.7.

230

Reafect ranked the patient with arginase I deficiency (ARG1) at 0.36%. This was considered to be a 231 232 relatively good ranking, since 14 metabolites were found to have a Z-score above 2.1, while the disease related metabolites arginine and ornithine had Z=2.1 and Z=-2.4 respectively. From a naive perspective 233 234 we would expect about 14 other enzyme deficiencies to have lower (better) rank than arginase I. However, 235 this relatively good performance can be explained by the fact that arginase I catalyzes the conversion of 236 arginine into ornithine (plus urea), and the substrate (arginine) is increased while the product (ornithine) is 237 reduced. Consequently, *Reafect* assigned a relatively high  $S_R$  score to this reaction. To strengthen this explanation, we used *Reafect* while flipping all Z-score signs (positive Z-scores become negative Z-scores 238 239 and vice versa), and we observe that for this patient the PR increased from 0.36% to 26.11% (Supplement 240 2, Figure S3). This demonstrates that the obtained PR (0.36%) was a consequence of taking the Z-score 241 signs and biochemical directionality into account.

242

Another interesting observation is the poor rank obtained for the patient having guanidinoacetate Nmethyltransferase deficiency (GAMT). This patient was under treatment with creatine supplementation, which explains the poor rank. Although guanidinoacetate (Z = 3.1) was high in this patient, the presence of the high creatine level (Z = 6.7) led to high Z-scores on both sides of the GAMT reaction R01883 which reduces the S<sub>R</sub> score, as can be observed in Equation 6 (Methods),

248

#### 249 Gene prioritization for IEM patients using CADD scores and Reafect

We hypothesized that potentially affected (metabolic) genes could be better prioritized when we combine the *CADD* (Phred) scores obtained from variants in WES data with the *deficient reaction scores* obtained from *Reafect*. Since an increase in both scores is expected to be associated with increased pathogenicity we chose to multiply the *deficient reaction score* with the maximum *CADD* score observed in the variants of the gene corresponding to that enzyme. Next, we used this combined score to rank the genes (Methods).

255

Since WES data was only available for two IEM patients, we evaluated this gene ranking based on two approaches: 1) using the WES background belonging to that patient if the WES was available (see asterisks in Table 1) and 2) using 15 random WES backgrounds while inserting the (known) disease-causing variant of the patient (Methods). Table 1 shows the PRs for 28 IEM patients for which the pathogenic variant was identified, using solely *Reafect*, solely *CADD* scores as well as the integrated approach. For 12/28 patients *Reafect* scored better than *CADD* (marked blue). For 21/28 and 20/28 patients, the integrated approach led

to improved ranking when compared only to *Reafect* or *CADD* scores, respectively. Especially the gain in ranking performance for patients 5 (ACADVL), 7 (ACAT1), 15 and 16 (GLDC), and 23 (OGDH) is noteworthy (marked orange).

265

Table 1. Overview of the IEM and disease-causing gene ranks for 28 IEM patients using *Reafect, CADD* scores and the integrated
approach. The first column indicates the patient, second columns the deficient enzyme with EC identifier. The third columns refers
to the affected gene. Next columns contain the PRs for each method as indicated by the column name; *Reafect* (only), *CADD* (only),
and the integrated approach. The approaches using the 15 random WES backgrounds report the mean, minimum and maximum
obtained PR across the 15 backgrounds. Blue marked results indicate that the PR of *Reafect* is lower than the PR of *CADD*. Orange
marked results indicate a clear improvement of the integrated approach over the individual approaches.
\* The PR for *CADD* was 0.24% using the real WES, and 0.0% for *Reafect with CADD* using the real WES.

<sup>\*\*</sup> The PR for *CADD* was 0.58% using the real WES, and 0.35% for *Reafect with CADD* using the real WES.

274


Patient	Enzyme	Gene	Reafect Percentile rank (%)	CADD Percentile rank (%) mean [min, max]	Reafect with CADD Percentile rank (%) mean [min, max]
				15 random WES backgrounds	15 random WES backgrounds
Patient 1	1.3.8.7	ACADM	1.71	0.4 [0.12,0.59]	0.0 [0.0,0.0]
Patient 2	1.3.8.7	ACADM	0.51	6.04 [5.33,7.16]	0.25 [0.11,0.36]
Patient 3	1.3.8.7	ACADM	3.59	0.41 [0.12,0.59]	0.11 [0.0,0.12]
Patient 4	1.3.8.7	ACADM	1.53	0.45 [0.12,0.64]	0.04 [0.0,0.12]
Patient 5	1.3.8.9	ACADVL	1.42	3.2 [1.85,4.22]	0.3 [0.12,0.5]
Patient 6	1.3.8.9	ACADVL	0.18	1.57 [1.03,2.07]	0.06 [0.0,0.24]
Patient 7	2.3.1.9	ACAT1	1.11	2.47 [1.33,3.52]	0.36 [0.24,0.62]
Patient 8	2.3.1.9	ACAT1	1.24	0.06 [0.0,0.23]	0.01 [0.0,0.12]
Patient 9	4.3.2.1	ASL	2.93	1.88 [1.19,2.6]	2.29 [2.02,2.59]
Patient 10	2.3.1.21	CPT2	9.01	0.73 [0.35,1.3]	4.3 [3.53,4.87]
Patient 11	2.3.1.21	CPT2	0	4.05 [2.78,5.15]	0.12 [0.0,0.25]
Patient 12	3.7.1.2	FAH	4.64	4.06 [2.41,5.38]	5.02 [4.48,5.59]
Patient 13	2.1.1.2	GAMT	28.99	0.05 [0.0,0.13]	5.26 [4.33,6.34]
Patient 14	1.3.8.6	GCDH	0.53	0.35 [0.11,0.59]	0.18 [0.0,0.46]
Patient 15	1.4.4.2	GLDC	4.09	2.26 [1.28,3.0]	0.64 [0.35,0.94]
Patient 16	1.4.4.2	GLDC	2.86	2.4 [1.31,3.17]	0.39 [0.11,0.66]
Patient 17	1.1.1.211	HADHA	0.54	1.04 [0.63,1.59]	0.11 [0.0,0.25]
Patient 17	4.2.1.17	HADHA	0.18	1.04 [0.63,1.59]	0.11 [0.0,0.25]
Patient 18 <sup>*</sup>	3.2.1.25	MANBA	0	0.42 [0.12,0.71]	0.0* [0.0,0.0]
Patient 19	6.4.1.4	MCCC2	0	7.0 [6.11,8.31]	0.04 [0.0,0.12]
Patient 20	5.4.99.2	MMUT	7.89	0.83 [0.35,1.42]	0.99 [0.46,1.27]
Patient 21	1.5.1.20	MTHFR	3.03	0.53 [0.12,0.97]	0.63 [0.35,0.93]
Patient 22	2.7.1.36	MVK	31.89	0.67 [0.35,1.3]	10.86 [9.78,11.59]
Patient 23	1.2.4.2	OGDH	1.83	8.04 [2.71,9.91]	0.13 [0.0,0.35]
Patient 24	2.1.3.3	OTC	6.7	0.51 [0.12,0.84]	1.32 [0.82,1.64]
Patient 25	1.14.16.1	PAH	0.18	2.08 [1.27,2.65]	0.0 [0.0,0.0]
Patient 26	1.14.16.1	PAH	0	1.22 [0.75,1.71]	0.0 [0.0,0.0]
Patient 27**	1.2.4.1	PDHA1	3.92	0.65 [0.34,1.09]	0.17 [0.11,0.36]
Patient 28	2.4.2.4	TYMP	0	0.46 [0.23,0.73]	0.0 [0.0,0.0]

275

To explore the overall differences in ranking performances between the three methods, we plotted the PRs in a boxplot (Figure 5). We removed the patient with guanidinoacetate N-methyltransferase deficiency from this analysis, arguing that the metabolic profile of this patient was not representative for this IEM because

279 of the treatment. Using the Mann-Whitney U test, we observe that the performance between *Reafect* and 280 CADD did not significantly differ (p-value > 0.05). However, the integrated approach significantly 281 (Wilcoxon signed-rank test, p-value < 0.05) improved the ranking performance when compared with solely using *Reafect* or *CADD* scores. In other words, by combining the two scores we gained improved IEM 282 283 ranking/ gene prioritization.

- 284
- 285



287

288 Figure 5. Boxplots of the percentile ranks (PRs) obtained from the different approaches; Reafect (only), CADD (only), and the 289 integrated approach. For CADD and the integrated approach we used the average PR obtained from the 15 random WES. 290 Significance was determined using the Wilcoxon signed-rank test (WSR) when comparing Reafect with CADD with CADD or 291 Reafect. We used the Mann-Whitney U test (MWU) for comparing CADD with Reafect, arguing that the PRs for CADD and Reafect 292 are independent since they are obtained from two separate datasets and approaches.

# 294 Discussion

295 Our aim was to use metabolomics data as additional evidence for filtering genetic variants found in WES 296 data. For this purpose, we developed *Reafect*, an algorithm that scores the efficacy of each reaction in a 297 pathway. To calculate these scores, *Reafect* combines four types of information: 1) the magnitude and 2) 298 sign of the metabolite Z-scores, 3) the biochemical directionality of reactions, and 4) the reaction distances 299 between the metabolites and a reactions in a pathway. We observed that *Reafect* ranked the true deficient 300 enzyme for 80% of the 72 IEM patient samples within the top 5% of all considered enzyme deficiencies. 301 *Reafect* showed improved ranking performance when compared to *MetPropagate*. We anticipate that this 302 improvement may at least partially be explained by three differences between *Reafect* and *MetPropagate*. 303 First, since *MetPropagate* uses cutoff values for the metabolite Z-scores when calculating the enrichment 304 scores, we expect relevant but subtle aberrant metabolites to be neglected. *Reafect* uses the Z-scores in a 305 continuous fashion, therefore even subtle aberrations contribute to the *deficient reaction scores* and 306 positively impact IEM ranking (see Supplement 6). Secondly, metabolite-gene set enrichment approaches 307 only consider metabolites which have a direct relationship with a gene, such as well-known biomarkers. 308 Metabolite levels which are multiple reaction steps away from the deficiency may still be informative but 309 will not contribute to the enrichment score when these metabolites are not included in the metabolite-gene 310 set. Thirdly, *MetPropagate*, and approaches like the ones suggested by Pirhaji et al. and Kerkhofs et al., do 311 not explicitly take the directionality of reactions and the sign of metabolite levels (decreased/increased) into 312 account. We showed that *Reafect*'s IEM ranking performance was greatly reduced by flipping the sign of 313 the metabolite Z-scores (Supplement 2), emphasizing that the Z-score sign and reaction directionality are 314 important for *Reafect*. We furthermore showed that by choosing optimal values for our model parameters 315 (a,b,c), we were able to improve the IEM ranking performance. Since these model parameters relate to the 316 interaction of the Z-score signs with reaction directionality, this again confirms that including this 317 information is valuable.

318

Integration of metabolomics with WES was achieved by multiplying the maximum *deficient reaction scores* with the maximum *CADD* score found for each enzyme and corresponding gene respectively (Methods). This integrated approach resulted in a significant improvement of ranking the true disease-causing genes (see Figure 5), where the median percentile rank (PR) was 1.36% lower than the median PR obtained from *Reafect*, and was 0.87% lower than the median PR obtained from using solely *CADD* scores.

In reality the human metabolome is one interconnected network of metabolites and reactions. In this study we have chosen to use isolated metabolic modules/pathways for two reasons. First, the (KEGG) pathways

327 are clusters of highly interdependent reactions, for which we expect multiple metabolite levels to be affected 328 if a pathway contains an enzymatic deficiency. Secondly, the direct use of a complete metabolic network 329 would introduce metabolic 'hubs' that would connect more distinct parts of the metabolism. This entanglement of pathways/reactions may have unwanted consequences for the deficient reaction scores 330 since also less relevant metabolite Z-scores would be involved in the calculation of these scores. A negative 331 332 consequence of using isolated modules/pathways might be that some important reactions are not included. 333 Although the goal was to develop an algorithm with minimum manual adjustments, we needed to add several reactions, such as glycine conjugation and carnitine esterification, to increase the overlap between 334 335 metabolites measured in plasma and the metabolites included in the pathways (Supplement 4).

336

337 *Reafect* also has some limitations. First, if not all metabolites in the KEGG pathway are measured and 338 annotated, this may lead to wrong conclusions. A single metabolite with a relatively high Z-score will cause all (downstream) reactions to have high *deficient reaction scores*. The inclusion of more measured 339 340 metabolites could prevent this behavior, since metabolite Z-scores with the same sign on both sides of the 341 reaction reduce the *deficient reaction score* (Methods, Equation 6). The IEM ranking performance of *Reafect* is therefore affected by the number of metabolites being measured within each pathway. Secondly, 342 343 *Reafect* is based on the assumption that IEM have the signature where substrates of the deficient reaction 344 become more abundant and the products decrease in abundancy. In case such signature does not hold for a 345 certain IEM, we expect *Reafect* to detect these kinds of IEM poorly. At last, *Reafect* ignores 346 compartmentalization of different metabolic processes. A substantial number of metabolic reactions occur 347 within certain compartments of the cell such as the mitochondrion. Similarly, different organs contain 348 different sets of metabolic reactions, therefore the concentration of the affected metabolites for an IEM may 349 be very different from the concentrations measured in plasma on which our Z-scores are based.

350

351 For most IEM patients with an identified disease-causing variant in this study, the putative gene was directly 352 sequenced, and therefore no WES data was obtained. We inserted the identified disease-causing variant in 353 15 random WES backgrounds, to enable the inclusion of these patients in our study. We assumed that the average ranking obtained from these 15 backgrounds was still a good estimate of the ranking which would 354 355 have been obtained when the real WES data was used. Due to our limited number of patients with real WES 356 data (N=2), a reliable comparison between both rankings is not possible, and thus we cannot validate the accuracy of this assumption. Note that the PRs obtained from the real WES fall within the minimum and 357 358 maximum PR obtained from the 15 WES backgrounds (Table 1).

360 *Reafect* uses only three decay factors (a, b, c) which we optimized using an overall performance metric (see 361 Results, Figure 2). Ideally, these decay factors are optimized using a training set while using a separate 362 validation set for evaluating the IEM ranking performances. Due to the low number of IEM patients included in this study we decided to use all samples for optimization and validation, arguing that splitting 363 364 the dataset into a training - and validation set would lead to less accurate estimates of the decay factors and 365 would give less insights into the overall performance of *Reafect* on distinct IEM. Note that we did use a 366 bootstrap procedure to prevent overfitting of the decay factors (Methods). To further support our findings, we separately optimized the decay factors using a subset of the 72 IEM patient samples; the 44 samples for 367 368 which the disease-causing variant was unknown. Using the same bootstrap procedure, we obtained an 369 optimum close to the one found when using all 72 samples (Supplement 5).

370

371 We realize that the use of three decay factors is a simplification, and that these factors should ideally be 372 reaction specific. Kinetic parameters, such as the Michaelis–Menten constant, could be used to establish 373 such reaction dependent decay factor. Currently accurate kinetic parameters are only available for a subset 374 of reactions. Besides the additional complexity introduced by these reaction specific decay factors, the use 375 of just three decay factors offered us the opportunity to demonstrate the overall importance of choosing 376 different decay factors for reaction directionality and the sign of the Z-score, as we clearly observed in 377 Figure 2. Still, we anticipate that *Reafect*'s performance on ranking IEM/genes could improve when 378 reaction specific decay factors are incorporated.

379

*Reafect* may not only be useful in the context of IEM but could be applicable in a wider context since the *deficient reaction scores* are a direct readout of potential accumulations and/or reductions of metabolites before/after a reaction. For example, *Reafect* is potentially useful in drug screening research for generating an overview of drug candidates which have the potential to inhibit metabolic enzymes. Namely, we expect that the inhibition of an enzyme by a drug will result in metabolic signatures similar to the ones caused by an IEM where the same enzyme is affected.

386

In conclusion, the integration of metabolomics data with WES data by using *Reafect's deficient reaction scores* and *CADD* scores, significantly improved the prioritization of pathogenic genes in patients suffering
 from an IEM.

- 390
- 391

# 392 Method

393

# 394 Untargeted metabolomics data and Z-scores

395 Metabolomics data was obtained as described by Bonte et al. Samples obtained from IEM patients were 396 measured in 20 separate batches and features were annotated using an in-house database having MS/MS 397 spectra and retention times of each metabolite (Bonte, et al., 2019). For the 72 patient samples, a median of 398 119 annotated metabolites was obtained (when combining positive - and negative ion mode), and a minimum of 95 annotated metabolites was available for each sample. In agreement with national legislation 399 400 and institutional guidelines, all patients or their guardians approved the possible anonymous use of the remainder of their samples for method validation and research purposes. The study was conducted in 401 accordance with the Declaration of Helsinki. Z-scores were calculated using two different approaches: 1) 402 403 metabolites which were annotated in at least 7 batches were merged, a Box-Cox transform was applied, 404 normalized using Metchalizer (Bongaerts, et al., 2020) and the Z-scores were determined using a regression 405 model with age and sex as covariates (Bongaerts, et al., 2020), 2) for metabolites which were annotated in 406 less than 7 batches, the Z-scores were determined from 15 within-batch samples, where abundancies were 407 first Box-Cox transformed and normalized using Probabilistic Quotient Normalization (PQN). When a 408 metabolite was annotated in both positive- and negative ion mode, the Z-score of the ion mode with the 409 largest median abundancy (over all samples) was taken. Since three technical replicates were measured for 410 all patient samples, we used the average of these three Z-scores as the final Z-score (which was then 411 transformed using Equation 1).

412

#### 413 Z-score transformation


To prevent extreme Z-scores to dominate the *deficient reaction scores*, we transformed the Z-score by applying:

416

417 
$$\tilde{Z} = \frac{\operatorname{sign}(Z)}{1 + \exp(2 - |Z|)} \left[ |Z|^{0.75} - |Z| \right] + Z$$
(1)

418

This transform behaves linear for the region 0 < |Z| < 2, but scales down Z-scores when |Z| >> 2 (Figure 6). 420



## 421

422 Figure 6. The effect of the transformation given by Equation 1 on the Z-scores.

423

#### 424 WES data

425 Whole Exome Sequencing (WES) data was acquired over a longer time period (2013-2021), and was performed either using the Agilent Clinical Research Exome V1 (sureselect SSCRE V1) or Agilent Clinical 426 427 Research Exome V2 (sureselect SSCRE V2) on a Illumina NovaSeq sequencer using paired-end reads with 428 a read-length of 150 bp. Reads were aligned to human reference genome build GRCh37/ hg19 429 (ucsc.hg19.nohap.fasta) using the BWA alignment algorithm (Li & Durbin, 2009). The VCF-files were obtained using GATK3 (McKenna, et al., 2010) and ANNOVAR was used to annotate gene names and 430 431 variants (Wang, et al., 2010). All patients included in this study from which WES data was used gave 432 consent for anonymous use of their data for research purposes.

433

#### 434 Retrieving human metabolic reactions

We used the KGML parser from <u>https://github.com/biopython/biopython</u> (20-03-2020) to process KEGG (Kanehisa, 2000) pathways and modules, where we filtered on reactions involved in humans (using the *hsa* pre-fix). When retrieving the KEGG networks, some reactions were associated with more than one enzyme, for which KEGG returns the same unique reaction as many times as it is associated with the different enzymes, leading to a multiplicity for these reactions. We removed this multiplicity but we remained all the associated enzymes with this reaction. In other words, in these cases the same S<sub>R</sub> score for that reaction was assigned to all associated enzymes.

442

To increase the overlap between the metabolites measured in plasma and metabolites in in the pathways/modules (from KEGG), we manually added some reactions. These can be found in Supplement 445 4. Most of these reactions were obtained from Recon / Virtual Metabolic Human (Noronha, et al., 2018).

# 446 **Reafect**

- 447 To determine the *deficient reaction score* for a certain reaction, we first consider the decay of the Z-score
  448 over a path *p* leading for metabolite *m* to reaction *R*:
- 449

$$E_{m,R,p}(Z_m) = \left(\prod_{s}^{\text{steps} \in p} \gamma_s\left(Z_m, D_s\right)\right) |Z_m|$$
(2)

451

450

Here,  $E_{m,R,p}(Z_m)$  is the *effective Z-score* for metabolite *m* from the perspective of reaction *R* along reaction path *p*.  $\gamma_s(Z_m, D_s)$  is the decay factor for step *s* and depends on the biochemical directionality of the step ( $D_s$ ) (upstream, downstream, reversible) and the sign of the Z-score ( $Z_m$ ):

455

$$\gamma_s(Z_m, D_s) = \begin{cases} a & \text{if } sgn(Z_m) = 1 \text{ and } D_s = \text{downstream} \\ a & \text{if } sgn(Z_m) = -1 \text{ and } D_s = \text{upstream} \\ b & \text{if } sgn(Z_m) = 1 \text{ and } D_s = \text{upstream} \\ b & \text{if } sgn(Z_m) = -1 \text{ and } D_s = \text{downstream} \\ c & \text{if } sgn(Z_m) = 1 \text{ and } D_s = \text{reversible} \\ c & \text{if } sgn(Z_m) = -1 \text{ and } D_s = \text{reversible} \end{cases}$$

$$(3)$$

456 457

For irreversible reactions, a is the decay factor for the Z-score when the sign of the Z-score is positive and the reaction step is downstream, or when the Z-score is negative and the reaction step is upstream. The parameter b is the decay factor for the opposite cases; the sign of the Z-score is positive (negative) and the reaction step is upstream (downstream). For reversible reactions we introduce parameter c as decay factor. Note that this decay is independent of the sign of the Z-score.

463

464 Since more paths (*p*'s) could be possible between metabolite *m* and reaction *R*, and these could have 465 different lengths, we calculated a normalized *effective Z-score* for every path:

466

$$\tilde{E}_{m,R,p} = \frac{\left[E_{m,R,p}(Z_m)\right]^2}{\sum_{p'} |E_{m,R,p'}(Z_m)|}$$
(4)

468

467

where  $E_{m,R,p}$  is the *normalized effective Z-score* for path p. The summation over p' indicates all paths leading from m to R. In this way, paths originating from m with (relatively) low *effective Z-score* strengths (such as longer paths) are weighted less in the *normalized effective Z-score* whereas short paths get more weight since their *effective Z-score* is relatively large (when compared to the other paths). All paths (p's)

were determined by constructing an 'ego graph' around each metabolite, selecting a subset of neighboring metabolites and reactions around this central metabolite. To reduce computational cost, we set a limit of 15 reaction steps (metabolite-reaction or reaction-metabolite) around this ego graph, and a maximum of 10 paths for travelling from m to R.

477

Next, we summed all normalized effective Z-scores but we made a distinction between normalized effective 478 479 Z-scores where its path is connected to the upstream or the downstream side of reaction R. For clarity, let 480 us consider a direct substrate m of reaction R, which has a direct connection at the upstream side of the 481 reaction. Let us also assume that there is a path going from m, via other reactions, which ends at the 482 downstream side of the reaction. Since we have two paths, we have two normalized effective Z-scores; one 483 belonging to the direct connection, the other belonging to the longer path. Since the latter path is longer, its 484 normalized effective Z-score will be less than the normalized effective Z-score of the direct connection (Equation 4). We aggregated all metabolite *normalized effective Z-scores* based on the Z-score sign and 485 486 connection to the reaction (downstream or upstream):

487

$$E_{\mathbf{x},\mathbf{y}}^{R} = \sum_{m \in \Omega_{\mathbf{x}}^{R}} \sum_{p \in \Omega_{\mathbf{y}}^{R}} \tilde{E}_{m,R,p}$$
5)

488 489

with  $x \in \{\text{positive Z-score}, \text{negative Z-score}\}, y \in \{\text{downstream}, \text{upstream}\}, \Omega_x^R \text{ indicates the set of} \\$ metabolites having a Z-score sign equal to x and  $\Omega_y^R$  indicates the set of paths from m to R which are connected to the y-side of reaction R (downstream or upstream). Since reversible reactions lack a clear defined up – and downstream side, we assigned one of each side to the up – or downstream side while making sure that product/substrate information was conserved.

495

496 Finally, we defined the *deficient reaction score* for reaction R as:

497

498

$$S_R = \begin{cases} \left(E_{+,\mathrm{up}}^R - E_{-,\mathrm{up}}^R\right) + \left(E_{-,\mathrm{down}}^R - E_{+,\mathrm{down}}^R\right) & \text{if reaction is irreversible} \\ \left|\left(E_{+,\mathrm{up}}^R - E_{-,\mathrm{up}}^R\right) + \left(E_{-,\mathrm{down}}^R - E_{+,\mathrm{down}}^R\right)\right| & \text{if reaction is reversible} \end{cases}$$

$$6)$$

499 500 where we replaced 'positive Z-score' and 'negative Z-score' for the symbol '+' and '-', respectively. We 501 replaced 'downstream' and 'upstream' for 'down' and 'up', respectively. We observe that  $S_R$  increases for 502 net positive *normalized effective Z-scores* located at the upstream side of the reaction and for net negative 503 *normalized effective Z-scores* located at the downstream side of the reaction, while  $S_R$  decreases for the

504 opposite cases. When a reaction is reversible we decided to take the absolute value, arguing that we are 505 interested in an imbalance of the net positive and negative *normalized effective Z-scores* across the reaction 506 regardless of which side of the reaction these *normalized effective Z-scores* were positioned.

507

We need to realize that some enzymes catalyze multiple (unique) reactions, which leads to a multiplicity of the  $S_R$  scores per enzyme and (potentially) shared reactions with other enzymes catalyzing the same reaction(s). In this study we dealt with this issue by taking the maximum occurring  $S_R$  score for each enzyme, even if that same  $S_R$  score was already assigned to another enzyme. Alternatively, we could have considered the use of another metric (other than the maximum) such as the average of all associated  $S_R$ scores, but since some associated reactions were considered poor, this average score could affect the performance negatively.

515

# 516 Overall performance of Reafect using bootstrapped AUC

517 Annotation of metabolites in the metabolomics data was performed per batch, which resulted in an unequal 518 number of annotations per batch. This difference also affected the number of unique enzymes on which 519 ranking was based per patient (Figure 4, Total number of enzymes). To correct for this, we expressed the 520 (absolute) rank in as a percentile by dividing by the total number of enzymes multiplied by 100%. The 521 overall performance of *Reafect* for a certain choice of (a, b, c) was measured by displaying the percentage 522 (vertical axis) of the IEM patients having the percentile rank of the correct IEM within the top x (horizontal 523 axis). Calculating the area under the curve (AUC) for this relationship gives a measure for the overall 524 performance, since a higher AUC indicates that a larger percentage of the IEM patients have a lower rank 525 (steeper increase of the curve). We used a bootstrap procedure where we selected 1000 times a random 75% of the total IEM patients for which we calculated the AUC. By taking the 50<sup>th</sup> percentile of these 1000 526 527 AUCs we obtained a more robust overall performance for each (a, b, c).

528

#### 529 MetPropagate and comparison with Reafect

530 We downloaded the weighted STRING network (v11) from <u>https://github.com/emmagraham/metPropagate</u> 531 (07-08-2020). ME scores were calculated in the exact same manner as described by Linck et al. Using the 532 same terminology, metabolites having |Z-score| > 1.5 where considered as 'differentially abundant 533 metabolites'. ME scores were propagated using the Local and Global Consistency (LGC) algorithm with 534 settings max\_iter=30 and alpha=0.99.

- 535
- 536 To objectively compare *Reafect* with *MetPropagate* we took several factors into account:

537 1) Only metabolites were included with (HMDB) identifiers in the pathways/modules used by *Reafect* 538 and which were also present in the gene-metabolite sets used by *MetPropagate*.

- Before determining ranks, the propagated ME scores for every gene were assigned to the associated
   enzyme(s). We removed genes (and thus enzymes) which did not overlap in the output of both
   algorithms. Thus, both outputs contained the exact same number of unique enzymes on which
   ranking was performed.
- 3) The ranks for *MetPropagate* were calculated using the propagated ME scores on the enzyme level.
  Note that we took the maximum propagated ME score for an enzyme when more genes were
  associated with that enzyme. Similarly, the ranks for *Reafect* were determined from the S<sub>R</sub> scores
  (as described above).
- 547

## 548 CADD scores

549 Variants called by GATK3 (see Method, WES data) were annotated with CADD scores from Genome build

550 GRCh37/ hg19 v1.6 (https://cadd.gs.washington.edu/download) for both SNVs and InDels. In this study

we used the *CADD* (Phred) scores in two manners: 1) ranking genes based solely on the maximum *CADD* 

score occurring in each gene and 2) ranking genes using the *deficient reaction score* (S<sub>R</sub> score) from *Reafect* 

combined with the *CADD* scores. Note, that only genes were included in this ranking for which a  $S_R$  score

- 554 was determined and which were present in the WES data.
- 555

556 Gene ranking using *Reafect* in combination with *CADD* scores was done as follow:

- 557 1) Per enzyme the maximum  $S_R$  score was determined for all associated reactions. For each enzyme, all 558 associated genes were determined and the same maximum  $S_R$  score was assigned to these genes.
- 559 2) The maximum *CADD* (Phred) score per gene was determined.

560 3) The  $S_R$  score (step 1) was multiplied with the *CADD* score (Phred) for each gene.

561 4) Genes were ranked on their integrated score (step 3).

562

For a subset of the IEM patients included in this study the disease-causing variant was identified either using whole exome sequencing (WES), Sanger sequencing or using an SNP array. Since WES data was not available for most IEM patients where the disease-causing variant(s) is identified, we assumed that we could include these patients using 15 random WES backgrounds while inserting the known disease-causing variant in each background. Consequently, we obtained 15 different rankings for each disease-causing gene. We assumed that the average of these 15 rankings is a good estimate of the rank when a real WES background was used (Discussion).

#### 571 Excluded IEM patients which were initially measured

572 Although some IEM patients were initially measured they were not included in this study, which had two 573 main reasons. First, in some cases there was no (clear) associated reaction related to the metabolites known as biomarkers for that IEM, e.g. defects in cofactor metabolism. For example, we left out a patient with a 574 575 mutation in the MMACHC gene, one with a mutation in the MOCS3 gene and two patients with glutaric 576 acidemia type 2 (ETFDH, ETFA, ETFB). Secondly, since *Reafect* does not make a distinction between 577 different compartments within the body or cell, the inclusion of enzymatic deficiencies related to transport 578 proteins is complicated. In these transport reactions the metabolite itself does not change, only its location 579 changes, and therefore build-up of these metabolites are expected only in certain parts of the body or cell ( 580 Discussion). For this reason, we were not able to include a few patients with lysinuric protein intolerance 581 (SLC7A7), and a patient with organic cation transporter 2 deficiency (SLC22A5) 582

583 Funding

584 This work was funded by the Erasmus Medical Centre, department of Clinical Genetics.

585

# 586 **Conflicts of Interest**

All authors state that they have no conflict of interest to declare. None of the authors accepted any reimbursements, fees, or funds from any organization that may in any way gain or lose financially from the results of this study. The authors have not been employed by such an organization. The authors do not have any other conflict of interest.

591

#### 592 Author contribution

The development of the methods was done by MB, MR and GR. RB performed all the experimental work, among which compound identification of the metabolomics data. MB developed the software and performed the computational experiments. WdV contributed in methods to analyze and process WES data. The interpretation of the results was done by MB, MR, HB and GR. The manuscript was written by MB, MR, HB and GR. SD, JL, HH and MW provided data and resources. The research was under supervision of GR.

599

## 600 Acknowledgement

We want to thank and acknowledge Professor Robert Hofstra for his support and Dr. Geert Geeven for hiscomments and feedback on the manuscript.

# 604 Code availability

605 *Reafect* is available at <u>https://github.com/mbongaerts/Reafect</u>

606

# 608 Supplementary data

609

# 610 Supplement 1. Comparison of ranks IEM patients *Reafect* versus *MetPropagate*

611

612

ACADM	27.16	2.01	BCKDH	52.5	0.37	IVD	59.07	3.15	PDHA1	15.2	3.56
ACADM	27.41	16.3	CBS	7.59	4.07	$IVD_a$	66.73	3.17	PSAT1	33.66	21.39
ACADM	29.07	19.26	CBS	9.86	2.13	$IVD_b$	59.53	2.53	PSAT1	35.84	12.08
ACADM	8.86	15.75	CBS	18.05	0.94	MANBA	79.17	93.56	TYMP	0.19	0.0
ACADM	5.74	21.3	CPS1	34.66	19.13	MCCC2	73.89	0.0	XDH	0.39	0.0
ACADM	35.19	15.19	CPS1	4.14	1.88	MLYCD	73.5	58.8		ink for gate	ink for t
ACADVL	10.88	0.38	CPT2	6.2	9.4	MTHFR	11.07	3.19		Percentile rank for MetPropagate	Percentile rank for Reafect
ACADVL	61.51	21.08	CPT2	0.19	0.0	MVK	68.61	31.39		Perce	Perce
ACAT1	30.17	1.35	CPT2	0.0	0.0	OAT	1.73	0.96			
ACAT1	32.59	1.21	FAH	45.66	3.7	OGDH	14.15	1.51			
ACSF3	65.16	15.35	FAH	72.47	5.06	отс	33.85	12.96			
ACY1	13.33	0.0	GAMT	0.0	27.92	OTC	33.52	11.81			
ADSL	0.38	0.0	GCDH	89.83	88.29	отс	9.62	6.6			
ARG1	2.32	0.0	GCDH	70.41	89.75	PAH	0.38	0.0			
ASL	1.33	3.24	GLDC	58.81	3.96	PAH	0.39	0.0			
ASL	0.58	0.0	HADHA	33.46	44.92	PAH	0.39	0.19			
ASL	1.29	0.37	HADHA	41.77	52.68	PAH	0.55	0.37			
$ASS_a$	0.93	0.0	HGD	61.7	36.42	PAH	0.98	2.76			
$ASS_b$	0.71	0.71	HGD	35.05	16.76	PCCA	1.38	0.79			
BCKDH	3.98	24.81	HMGCL	26.45	27.77	PCCA	47.59	2.59			
	Percentile rank for MetPropagate	Percentile rank for Reafect		Percentile rank for MetPropagate	Percentile rank for Reafect		Percentile rank for MetPropagate	Percentile rank for Reafect			

613

614 Figure S1. Comparison of the percentile ranks between *Reafect* and *MetPropagate* per IEM patient.

# 616 Supplement 2. The effect of flipping the Z-score on IEM ranking performance

617

618 To explore the importance of taking the biochemical directionality and the sign of the Z-scores into account,


619 we flipped the sign for all Z-scores (in all patients), and used *Reafect* to rank the enzymatic deficiencies

620 (Figure S2). We observe that the AUC was reduced by 26%, and for the lower region of the performance

621 curve (<10%), the partial AUC even dropped by 61%. These results underline the importance of including

this information when considering IEM ranking algorithms. A detailed comparison between the ranks

- 623 obtained from both approaches can be found in Figure S3.
- 624



627 Figure S2. A) Full performance curves for *Reafect* and *Reafect with flipped Z-score signs*. B) Percentile ranks <= 10%.


ACADM	1.71	8.38	BCKDH	4.19	2.62	HGD	36.23	73.73	PAH	0.0	99.82
ACADM	3.76	3.08	CBS	2.13	4.09	HGD	18.46	57.04	PAH	0.0	100.0
ACADM	0.36	6.87	CBS	3.76	9.4	HMGCL	0.36	4.99	PAH	0.54	99.82
ACADM	0.51	17.09	CBS	0.87	6.93	HPRT1	0.54	6.45	PAH	0.18	99.82
ACADM	3.59	6.15	CP51	19.37	24.61	IVD	1.54	4.1	PAH	2.86	100.0
ACADM	1.53	21.56	CP51	1.73	2.95	$IVD_a$	3.16	7.81	PCCA	0.76	5.15
ACADVL	1.42	24.16	CPT2	0.0	0.0	$IVD_b$	0.19	2.79	PCCA	2.39	12.82
ACADVL	0.18	10.7	CPT2	9.01	10.75	MANBA	0.0	100.0	PDHA1	3.92	27.63
ACAT1	1.11	46.2	CPT2	0.0	0.0	MCCC2	0.0	99.83	PSAT1	19.89	28.62
ACAT1	1.24	43.34	FAH	3.77	94.61	MLYCD	10.3	3.55	PSAT1	6.88	37.55
ACSF3	17.94	52.1	FAH	4.64	95.36	MMUT	0.0	13.61	TYMP	0.0	0.35
ACY1	0.0	0.0	GAMT	28.99	0.18	MMUT	7.89	26.88	XDH	0.0	2.61
ADSL	0.0	0.17	GCDH	0.18	100.0	MMUT	1.64	26.0		nk for	eafect sign
ARG1	0.36	26.11	GCDH	0.53	100.0	MTHFR	3.03	47.95		Percentile rank for Reafect	k for R. Z-score
ASL	2.93	9.14	GLDC	1.01	36.97	MVK	31.89	98.79		Perce	Percentile rank for Reafect with flipped Z-score sign
ASL	0.0	3.73	GLDC	2.52	20.0	OAT	88.0	88.0			Percen with 1
ASL	0.36	4.67	GLDC	4.09	37.17	OGDH	1.83	32.72			
$ASS_a$	0.0	2.74	GLDC	2.86	11.93	отс	13.32	7.46			
$ASS_b$	0.0	13.97	HADHA	0.54	0.54	отс	6.7	9.42			
BCKDH	0.36	22.26	HADHA	1.62	2.33	отс	11.88	1.1			
	Percentile rank for Reafect	Percentile rank for Reafect with flipped Z-score sign		Percentile rank for Reafect	Percentile rank for Reafect with flipped Z-score sign		Percentile rank for Reafect	Percentile rank for Reafect with flipped Z-score sign			

629


630 Figure S3. Comparison of the percentile ranks between *Reafect* and *Reafect with flipped Z-score signs* per IEM patient. We clearly

631 observe the negative effect of reversing the sign of the Z-scores on ranking.

632







636

Figure S4. Each boxplot indicates the distribution of the *CADD* (Phred) scores for variants in metabolic genes obtained in 15
random WES files. The last boxplot shows the *CADD* scores (Phred) for the disease-causing variants found in the IEM patients
(Table 1).

# 641 Supplement 4. Manually added reactions

- 642
- 643 The KEGG pathways and modules were extended with some additional reactions (see Table S1) to increase
- 644 the overlap between metabolites present in the pathways/modules and metabolites measured in plasma.
- 645 Note, that a reaction is defined as a graph which also includes a reaction node.
- 646
- 647 Table S1. Manually added reactions. The second and fourth column indicate the directionality of the reaction. '<=>' indicates that
- 648 the reaction is reversible whereas '=>' indicates the direction of an irreversible reaction. Note that these 'reactions' passes through
- a reaction node (Reaction ID). Most reactions originate from Recon3D.

Metabolite 1		Reaction ID		Metabolite 2
3-Hydroxypyruvic acid	=>	HPYRR2x	=>	Glyceric acid
2-Methylbutyrylglycine	<=>	RE2428M	<=>	2-Methylbutanoyl-CoA
2-Methylbutyrylglycine	<=>	RE2428M	<=>	Glycine
C16OH   3-Hydroxyhexadecanoylcarnitine	<=>	C16OHc	<=>	(S)-3-Hydroxyhexadecanoyl-CoA
3-Methylcrotonylglycine	<=>	RE2111M	<=>	3-Methylcrotonyl-CoA
3-Methylcrotonylglycine	<=>	RE2111M	<=>	Glycine
glcnac-man	=>	B_MANNASEly	=>	N-Acetyl-D-glucosamine
glcnac-man	=>	B_MANNASEly	=>	D-Mannose
C10   Decanoylcarnitine	<=>	C100CPT1	<=>	Decanoyl-CoA
Glycylproline	<=>	GLYPROPRO1c	<=>	Glycine
Glycylproline	<=>	GLYPROPRO1c	<=>	Proline
C6   Hexanoylcarnitine	<=>	C60CPT1	<=>	Hexanoyl-CoA
Homocysteine thiolactone	<=>	RE1933C	<=>	Homocysteine
Isobutyrylglycine	<=>	RE2429M	<=>	Glycine
Isobutyrylglycine	<=>	RE2429M	<=>	2-Methylpropanoyl-CoA
C5   Isovalerylcarnitine	<=>	C50CPT1	<=>	3-Methylbutanoyl-CoA
Isovalerylglycine	<=>	RE2427M	<=>	Glycine
Isovalerylglycine	<=>	RE2427M	<=>	3-Methylbutanoyl-CoA
Malonyl-CoA	=>	r0430	=>	C3DC   Malonylcarnitine
N-Acetylasparagine	<=>	RE2032M	<=>	Asparagine
C14   Tetradecanoylcarnitine	<=>	C140CPT1	<=>	Tetradecanoyl-CoA
C5:1   Tiglylcarnitine	<=>	C51CPT1	<=>	2-Methylbut-2-enoyl-CoA
Octanoyl-CoA	<=>	C80CPT1	<=>	C8   Octanoylcarnitine
Butanoyl-CoA	<=>	C40CPT1	<=>	C4   Butyrylcarnitine
Propanoyl-CoA	<=>	C30CPT1	<=>	C3   Propionylcarnitine
(2S,3S)-3-Hydroxy-2-methylbutanoyl-CoA	<=>	R 2M3HBUc	<=>	2-Methyl-3-hydroxybutyric acid
2-Methylbut-2-enoyl-CoA	<=>	R TIGGLYc	<=>	Tiglylglycine
N-Acetylmethionine	<=>	RE2640C	<=>	Methionine
N-Acetylalanine	<=>	RE2642C	<=>	L-Alanine
Glutaryl-CoA	<=>	FAOXC5C5DCc	<=>	C5DC   Glutarylcarnitine
3-Methylglutaconyl-CoA	<=>	3mgcoac61dcmgccrn	<=>	C6:1DC   3-Methylglutaconylcarnitine
3-Methylglutaconyl-CoA	<=>	MGCHrm	<=>	(S)-3-Hydroxy-3-methylglutaryl-CoA
(S)-3-Hydroxy-3-methylglutaryl-CoA	<=>	hmgcoac6dcmgcrn	<=>	C6DC   3-Methylglutarylcarnitine
3-Hydroxyisovaleryl-CoA	<=>	C059983ivcrn	<=>	C5OH   3-Hydroxyisovalerylcarnitine
3-Hydroxyisovaleryl-CoA	<=>	C059983CE2028	<=>	3-Hydroxyisovaleric acid
Adenylosuccinate	=>	C03794succinyladenosine	=>	Succinyladenosine
L-Aspartate	=>	ASPCTr	=>	N-Carbamoyl-L-aspartate
Carbamoylphosphate	=>	ASPCTr	=>	N-Carbamoyl-L-aspartate
Dihydroorotic acid	=>	DHORTS	=>	N-Carbamoyl-L-aspartate
Dihydroorotic acid	<=>	DHORD9	<=>	Orotic acid
Malonate	=>	C00383malcoa	=>	Malonyl-CoA
Malonyl-CoA	=>	MCDm	=>	Acetyl-CoA
7-Dehydrocholesterol	=>	HMR_2114	=>	Vitamine D3
Cholesterol sulfate	<=>	RE1100L	<=>	Cholesterol

650

651

# 653 Supplement 5. Optimizing the decay factors while excluding the samples with an identified disease-654 causing variant

655

In this study we used all 72 IEM patients samples to optimize the decay factors and to evaluate *Reafect*'s 656 657 performance on IEM/gene ranking. To support our findings, especially for the results where we integrated 658 the deficient reaction scores with CADD scores (Table 1), we optimized the decay factors on 44/72 samples 659 where we excluded the patients with an identified disease-causing variant. We used the same bootstrap 660 procedure for determining the optimal values for the decay factors (Methods). We found that the optimum was at a = 0.85, b = 0.45, c = 0.75 (100%), and the second best combination was a = 0.85, b = 0.35, c = 0.35, c661 662 0.75 (99.96%) (Figure S5). However, we also observe that the optimum is wider and less well-defined as 663 the one observed in Figure 2.

664






Figure S5. A) Bootstrapped AUCs (Methods) for given combinations of (a,b,c) indicating the performance of *Reafect*. The colors indicate the percentage of the maximum obtained AUC. For this analysis we used 44/72 IEM patients samples, where we excluded

668 the patients with an identified disease-causing variant. **B**) Contour plot of the (cubic interpolated) bootstrapped AUCs while fixing

669 c=0.75 and varying a and b. The contour levels indicate the percentage of the maximum AUC reached at a = 0.85, b = 0.45, c = 0

- **670** *0.75*.
- 671

#### 672 Supplement 6. Contribution of subtle metabolite Z-scores on IEM ranking

673

We explored the contribution of more subtle metabolite Z-scores to the IEM ranking performance of 674 *Reafect.* This was investigated by creating performance curves for various Z-score cutoffs, where we 675 676 included only metabolite Z-scores for which |Z-score| < cutoff (Figure S6A) or |Z-score| > cutoff (Figure 677 S6B). These results show that for decreasing cutoff values and |Z-score| < cutoff, the overall performance 678 on IEM ranking also declines. This can be understood by realizing that for decreasing cutoff values, also 679 more informative (disease-related) metabolites are excluded. More importantly, we observe that even for 680 the lower cutoff values the overall performance is still positive (above the diagonal line), suggesting that 681 more subtle metabolite Z-scores also contribute to IEM ranking. The same conclusion can be drawn from 682 the experiment where we included only metabolites having a |Z-score| > cutoff. When increasing the cutoff 683 values, we observe that the IEM ranking performance also decreases. Since in these cases only more 684 extreme Z-scores are available for ranking, we conclude that more subtle metabolite Z-scores normally also 685 contribute to IEM ranking.








Figure S6. A) Full performance curves for *Reafect* for various Z-score cutoff values, and |Z-score| < cutoff. Cutoff values are</li>
indicated by the legend. B) Full performance curves for *Reafect* for various Z-score cutoff values, and |Z-score| > cutoff.

# 691 **References**

- Alaimo, J. T. et al., 2020. Integrated analysis of metabolomic profiling and exome data supplements
- 693 sequence variant interpretation, classification, and diagnosis. *Genetics in Medicine*, 5.
- Baumgartner, C. et al., 2004. Supervised machine learning techniques for the classification of metabolic
  disorders in newborns. *Bioinformatics*, 6, Volume 20, p. 2985–2996.
- Bongaerts, M. et al., 2020. Using Out-of-Batch Reference Populations to Improve Untargeted
- 697 Metabolomics for Screening Inborn Errors of Metabolism. *Metabolites*, 12, Volume 11, p. 8.
- Bonte, R. et al., 2019. Untargeted Metabolomics-Based Screening Method for Inborn Errors of
- Metabolism using Semi-Automatic Sample Preparation with an UHPLC- Orbitrap-MS Platform.
   *Metabolites*, 11, Volume 9, p. 289.
- 701Haijes, H. A. et al., 2020. Untargeted Metabolomics for Metabolic Diagnostic Screening with Automated
- Data Interpretation Using a Knowledge-Based Algorithm. *International Journal of Molecular Sciences*, 2,
  Volume 21, p. 979.
- Kanehisa, M., 2000. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Research*, 1,
  Volume 28, p. 27–30.
- Kerkhofs, M. H. P. M. et al., 2020. Cross-Omics: Integrating Genomics with Metabolomics in Clinical
  Diagnostics. *Metabolites*, 5, Volume 10, p. 206.
- Lee, J. J. Y. et al., 2017. Knowledge base and mini-expert platform for the diagnosis of inborn errors of
  metabolism. *Genetics in Medicine*, 7, Volume 20, p. 151–158.
- Li, H. & Durbin, R., 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics*, 5, Volume 25, p. 1754–1760.
- Linck, E. J. G. et al., 2020. metPropagate: network-guided propagation of metabolomic information for
  prioritization of metabolic disease genes. *npj Genomic Medicine*, 7.Volume 5.
- McKenna, A. et al., 2010. The Genome Analysis Toolkit: A MapReduce framework for analyzing nextgeneration DNA sequencing data. *Genome Research*, 7, Volume 20, p. 1297–1303.
- Messa, G. M. et al., 2020. A Siamese neural network model for the prioritization of metabolic disorders
  by integrating real and simulated data. *Bioinformatics*, 12, Volume 36, p. i787–i794.
- Noronha, A. et al., 2018. The Virtual Metabolic Human database: integrating human and gut microbiome
  metabolism with nutrition and disease. *Nucleic Acids Research*, 10, Volume 47, p. D614–D624.
- Pirhaji, L. et al., 2016. Revealing disease-associated pathways by network integration of untargeted
  metabolomics. *Nature Methods*, 8, Volume 13, p. 770–776.
- 722 Pronicka, E. et al., 2016. New perspective in diagnostics of mitochondrial disorders: two years'
- 723 experience with whole-exome sequencing at a national paediatric centre. Journal of Translational
- 724 *Medicine*, 6.Volume 14.
- Rentzsch, P. et al., 2018. CADD: predicting the deleteriousness of variants throughout the human
- genome. *Nucleic Acids Research*, 10, Volume 47, p. D886–D894.

- 727 Stavropoulos, D. J. et al., 2016. Whole-genome sequencing expands diagnostic utility and improves
- clinical management in paediatric medicine. *npj Genomic Medicine*, 1.Volume 1.
- 729 Thiele, I. et al., 2013. A community-driven global reconstruction of human metabolism. *Nature*
- 730 *Biotechnology*, 3, Volume 31, p. 419–425.
- 731 Wang, K., Li, M. & Hakonarson, H., 2010. ANNOVAR: functional annotation of genetic variants from
- high-throughput sequencing data. *Nucleic Acids Research*, 7, Volume 38, p. e164–e164.
- Waters, D. et al., 2018. Global birth prevalence and mortality from inborn errors of metabolism: a
  systematic analysis of the evidence. *Journal of Global Health*, 11.Volume 8.
- 735 Wright, C. F., FitzPatrick, D. R. & Firth, H. V., 2018. Paediatric genomics: diagnosing rare disease in
- rildren. *Nature Reviews Genetics*, 2, Volume 19, p. 253–268.
- 737